Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atacicept
- Development stage
- Approved
- Lead developer
- Vera Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Atacicept is an investigational **recombinant fusion protein** and dual **BAFF/APRIL** antagonist designed to suppress B-cell survival and plasma-cell activity by binding the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand. The molecule consists of the extracellular ligand-binding domain of **TACI** fused to the Fc portion of human IgG, and has been studied in autoimmune diseases including systemic lupus erythematosus and lupus nephritis, with current late-stage development led by **Vera Therapeutics** for **IgA nephropathy**. Vera obtained exclusive worldwide rights from **Ares Trading**, an affiliate of **Merck KGaA**, in 2020; atacicept is positioned as a potential first-in-class therapy in IgA nephropathy and has also been explored clinically in lupus-related indications.
- Other names
- atacicept
02
Targets
TNFSF13 (APRIL)BAFF (Tumor necrosis factor ligand superfamily member 13B)
Beyond the preview
Go deeper on atacicept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atacicept.